English  |  正體中文  |  简体中文  |  2809353  
???header.visitor??? :  26911261    ???header.onlineuser??? :  450
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"mulla s"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-3 of 3  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-02-21T02:04:35Z Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG
臺大學術典藏 2022-02-21T02:04:34Z Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M.
臺大學術典藏 2021-08-31T06:29:17Z Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators

Showing items 1-3 of 3  (1 Page(s) Totally)
1 
View [10|25|50] records per page